Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 330,531 | 108,463 | 48,661 | 335,659 | 26,678 |
| Gross Profit | 330,531 | 108,463 | 48,661 | 335,659 | 26,678 |
| Operating Expenses | 527,230 | 449,207 | 344,412 | 272,941 | 239,862 |
| Operating Income | -196,699 | -340,744 | -295,751 | 62,718 | -213,184 |
| Other Income | 51,505 | 14,774 | 4,595 | 9,241 | 15,219 |
| Pre-tax Income | -145,194 | -325,970 | -291,156 | 71,959 | -197,965 |
| Income Tax | 30 | 21 | -575 | 823 | -351 |
| Net Income Continuous | -145,224 | -325,991 | -290,581 | 71,136 | -197,614 |
| Net Income | $-145,224 | $-325,991 | $-290,581 | $71,136 | $-197,614 |
| EPS Basic Total Ops | -1.06 | -2.60 | -2.39 | 0.65 | -2.07 |
| EPS Basic Continuous Ops | -1.06 | -2.60 | -2.39 | 0.65 | -2.07 |
| EPS Diluted Total Ops | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 |
| EPS Diluted Continuous Ops | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 |
| EPS Diluted Before Non-Recurring Items | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 |
| EBITDA(a) | $-223,925 | $-331,998 | $-278,410 | $71,304 | $-210,212 |